Alkem Laboratories on Wednesday announced the launch of NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.
The company stated that cenobamate is being launched for the first time in India, where an estimated 94 lakh people live with epilepsy.
NeuCeno is a once-daily oral therapy available in strengths ranging from 12.5 mg to 200 mg tablets.
In clinical studies of adults with uncontrolled focal seizures on existing medications, adjunctive cenobamate showed up to a 78 per cent reduction in seizure frequency, with up to 30 per cent of patients achieving seizure freedom during the maintenance phase, the company said in an exchange filing.
“People living with epilepsy and their caregivers face significant challenges in achieving effective seizure control. Cenobamate has the potential to transform treatment outcomes towards delivering better epilepsy management,” said Sandeep Singh, Managing Director of Alkem Laboratories.
Published on September 16, 2026
